{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:09:48Z","timestamp":1777039788824,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Public Ministry of Labor Campinas (Research, Prevention, and Education of Occupational Cancer) in Campinas, Brazil"},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12029-023-00964-x","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:01:48Z","timestamp":1692756108000},"page":"344-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer"],"prefix":"10.1007","volume":"55","author":[{"given":"Florinda A.","family":"Santos","sequence":"first","affiliation":[]},{"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[]},{"given":"Lucas C.","family":"Barroti","sequence":"additional","affiliation":[]},{"given":"Allan A. L.","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Marcus M.","family":"Matsushita","sequence":"additional","affiliation":[]},{"given":"Ana Carolina","family":"de Carvalho","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Guilherme","family":"Datorre","sequence":"additional","affiliation":[]},{"given":"Gustavo N.","family":"Berardinelli","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7834-5944","authenticated-orcid":false,"given":"Raphael L. C.","family":"Araujo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"964_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: a cancer journal for clinicians. 2022.","DOI":"10.3322\/caac.21708"},{"issue":"1","key":"964_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1568026614666140423121525","volume":"9","author":"F Meriggi","year":"2014","unstructured":"Meriggi F, Vermi W, Bertocchi P, Zaniboni A. The emerging role of NRAS mutations in colorectal cancer patients selected for anti-EGFR therapies. Rev Recent Clin Trials. 2014;9(1):8\u201312.","journal-title":"Rev Recent Clin Trials"},{"key":"964_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0959-8049(01)00233-7","volume":"37","author":"J Baselga","year":"2001","unstructured":"Baselga J. The EGFR as a target for anticancer therapy\u2014focus on cetuximab. Eur J Cancer. 2001;37:16\u201322.","journal-title":"Eur J Cancer"},{"issue":"4","key":"964_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337\u201345.","journal-title":"N Engl J Med"},{"issue":"20","key":"964_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040\u20138.","journal-title":"N Engl J Med"},{"issue":"8","key":"964_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","volume":"11","author":"W De Roock","year":"2010","unstructured":"De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753\u201362.","journal-title":"Lancet Oncol"},{"key":"964_CR7","doi-asserted-by":"crossref","unstructured":"Di Nicolantonio F, Martini M, Molinari F, Sartore Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. 2008.","DOI":"10.1200\/JCO.2008.18.0786"},{"issue":"20","key":"964_CR8","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","volume":"117","author":"B Tran","year":"2011","unstructured":"Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117(20):4623\u201332.","journal-title":"Cancer"},{"issue":"5","key":"964_CR9","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.3390\/ijms24054868","volume":"24","author":"AS Martianov","year":"2023","unstructured":"Martianov AS, Mitiushkina NV, Ershova AN, Martynenko DE, Bubnov MG, Amankwah P, et al. KRAS, NRAS, BRAF, HER2 and MSI status in a large consecutive series of colorectal carcinomas. Int J Mol Sci. 2023;24(5):4868.","journal-title":"Int J Mol Sci"},{"key":"964_CR10","doi-asserted-by":"crossref","unstructured":"Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471\u20134.","DOI":"10.1245\/s10434-010-0985-4"},{"issue":"4","key":"964_CR11","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3892\/or.2014.3338","volume":"32","author":"L Yamane","year":"2014","unstructured":"Yamane L, Scapulatempo-Neto C, Alvarenga L, Oliveira C, Berardinelli G, Almodova E, et al. KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy. Oncol Rep. 2014;32(4):1419\u201326.","journal-title":"Oncol Rep"},{"issue":"47","key":"964_CR12","doi-asserted-by":"publisher","first-page":"28691","DOI":"10.18632\/oncotarget.25611","volume":"9","author":"GN Berardinelli","year":"2018","unstructured":"Berardinelli GN, Scapulatempo-Neto C, Dur\u00e3es R, de Oliveira MA, Guimar\u00e3es D, Reis RM. Advantage of HSP110 (T17) marker inclusion for microsatellite instability (MSI) detection in colorectal cancer patients. Oncotarget. 2018;9(47):28691.","journal-title":"Oncotarget"},{"issue":"3","key":"964_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","volume":"28","author":"A Roth","year":"2009","unstructured":"Roth A, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60\u201300 trial. J Clin Oncol: Official J Am Soc Clin Oncol. 2009;28(3):466\u201374.","journal-title":"J Clin Oncol: Official J Am Soc Clin Oncol"},{"key":"964_CR14","unstructured":"Berardinelli GN. Elucida\u00e7\u00e3o do impacto molecular e cl\u00ednico da instabilidade de microssat\u00e9liteem pacientes com c\u00e2ncer colorretal do Hospital de C\u00e2ncer de Barretos. 2017."},{"issue":"5","key":"964_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","volume":"51","author":"F Pietrantonio","year":"2015","unstructured":"Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015;51(5):587\u201394.","journal-title":"Eur J Cancer"},{"issue":"D1","key":"964_CR16","doi-asserted-by":"publisher","first-page":"D805","DOI":"10.1093\/nar\/gku1075","volume":"43","author":"SA Forbes","year":"2015","unstructured":"Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(D1):D805\u201311.","journal-title":"Nucleic Acids Res"},{"key":"964_CR17","doi-asserted-by":"crossref","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal.\u00a02013;6(269):pl1\u2013pl.","DOI":"10.1126\/scisignal.2004088"},{"key":"964_CR18","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Sandoval JA, Guti\u00e9rrez-Angulo M, Maga\u00f1a-Torres MT, Alvizo-Rodr\u00edguez CR, Ram\u00edrez-Plascencia HHF, Flores-L\u00f3pez BA, et al. Prevalence of the BRAF p. v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations. J Investig Med. 2020;68(5):985\u201391.","DOI":"10.1136\/jim-2020-001301"},{"key":"964_CR19","doi-asserted-by":"crossref","unstructured":"Dur\u00e3es RO, Berardinelli GN, Da Costa AM, Scapulatempo-Neto C, Pereira R, Oliveira MA, et al. Role of genetic ancestry in 1,002 Brazilian colorectal cancer patients from Barretos Cancer Hospital. Front Oncol. 2020:145.","DOI":"10.3389\/fonc.2020.00145"},{"key":"964_CR20","doi-asserted-by":"crossref","unstructured":"Pereira AAL, Fernandes GDS, Braga GT, Marchetti KR, do Couto Mascarenhas C, Gumz B, et al. Differences in pathology and mutation status among colorectal cancer patients younger than, older than, and of screening age. Clin Colorectal Cancer. 2020;19(4):e264\u2013e71.","DOI":"10.1016\/j.clcc.2020.06.004"},{"issue":"1","key":"964_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"W Dos Santos","year":"2019","unstructured":"Dos Santos W, Sobanski T, De Carvalho AC, Evangelista AF, Matsushita M, Berardinelli GN, et al. Mutation profiling of cancer drivers in Brazilian colorectal cancer. Sci Rep. 2019;9(1):1\u201313.","journal-title":"Sci Rep"},{"issue":"3","key":"964_CR22","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s11033-011-1007-8","volume":"39","author":"CG Rasuck","year":"2012","unstructured":"Rasuck CG, Leite SM, Komatsuzaki F, Ferreira AC, Oliveira VC, Gomes KB. Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients. Mol Biol Rep. 2012;39(3):2553\u201360.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"964_CR23","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/bjc.2011.19","volume":"104","author":"T Yokota","year":"2011","unstructured":"Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104(5):856\u201362.","journal-title":"Br J Cancer"},{"key":"964_CR24","doi-asserted-by":"crossref","unstructured":"Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer\u2014results from NCIC CTG\/AGITG CO. 17. Clin Cancer Res. 2014;20(3):744\u201353.","DOI":"10.1158\/1078-0432.CCR-13-0606"},{"issue":"12","key":"964_CR25","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/bjc.2015.173","volume":"112","author":"A Rowland","year":"2015","unstructured":"Rowland A, Dias M, Wiese M, Kichenadasse G, McKinnon R, Karapetis C, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112(12):1888\u201394.","journal-title":"Br J Cancer"},{"key":"964_CR26","doi-asserted-by":"crossref","unstructured":"Stintzing S, Heinrich K, Tougeron D, Modest DP, Schwaner I, Euker J, et al. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: the phase-II FIRE-4.5 study (AIO KRK-0116). Wolters Kluwer Health.\u00a02021.","DOI":"10.1200\/JCO.2021.39.15_suppl.3502"},{"key":"964_CR27","doi-asserted-by":"crossref","unstructured":"Ciombor KK, Strickler JH, Bekaii-Saab TS, Yaeger R. BRAF-mutated advanced colorectal cancer: a rapidly changing therapeutic landscape. J Clin Oncol. 2022:JCO. 21.02541.","DOI":"10.1200\/JCO.21.02541"},{"issue":"4","key":"964_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39(4):273\u201384.","journal-title":"J Clin Oncol"},{"issue":"3","key":"964_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/PDM.0b013e3181c93fd1","volume":"19","author":"N Irahara","year":"2010","unstructured":"Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, et al. NRAS mutations are rare in colorectal cancer. Diagnostic molecular pathology: the American journal of surgical pathology, part B. 2010;19(3):157.","journal-title":"Diagnostic molecular pathology: the American journal of surgical pathology, part B"},{"issue":"25","key":"964_CR30","doi-asserted-by":"publisher","first-page":"20785","DOI":"10.18632\/oncotarget.4750","volume":"6","author":"M Morkel","year":"2015","unstructured":"Morkel M, Riemer P, Bl\u00e4ker H, Sers C. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget. 2015;6(25):20785.","journal-title":"Oncotarget"},{"issue":"13","key":"964_CR31","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306\u201315.","journal-title":"Lancet Oncol"},{"issue":"7407","key":"964_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"CGA Network","year":"2012","unstructured":"Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330.","journal-title":"Nature"},{"key":"964_CR33","first-page":"159","volume":"17","author":"JN Nojadeh","year":"2018","unstructured":"Nojadeh JN, Sharif SB, Sakhinia E. Microsatellite instability in colorectal cancer. EXCLI J. 2018;17:159.","journal-title":"EXCLI J"},{"issue":"2","key":"964_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","volume":"100","author":"M Koopman","year":"2009","unstructured":"Koopman M, Kortman G, Mekenkamp L, Ligtenberg M, Hoogerbrugge N, Antonini N, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266\u201373.","journal-title":"Br J Cancer"},{"issue":"5","key":"964_CR35","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/annonc\/mds614","volume":"24","author":"M Merok","year":"2013","unstructured":"Merok M, Ahlquist T, R\u00f8yrvik E, Tufteland K, Hektoen M, Sjo O, et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol. 2013;24(5):1274\u201382.","journal-title":"Ann Oncol"},{"key":"964_CR36","doi-asserted-by":"crossref","unstructured":"M\u00fcller C, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO colorectal study group. Int J Colorectal Dis. 2008;23(11):1033\u20139.","DOI":"10.1007\/s00384-008-0504-2"},{"issue":"5","key":"964_CR37","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3816\/CCC.2010.n.041","volume":"9","author":"AC Buzaid","year":"2010","unstructured":"Buzaid AC, de Cerqueira MC, Perazzo F, Simon SD, Fein L, Hidalgo J, et al. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study. Clin Colorectal Cancer. 2010;9(5):282\u20139.","journal-title":"Clin Colorectal Cancer"},{"issue":"14","key":"964_CR38","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3748\/wjg.v17.i14.1879","volume":"17","author":"R Lim","year":"2011","unstructured":"Lim R, Sun Y, Im S-A, Hsieh R-K, Yau TK, Bonaventura A, et al. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study. World J Gastroenterol: WJG. 2011;17(14):1879.","journal-title":"World J Gastroenterol: WJG"},{"issue":"33","key":"964_CR39","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1200\/JCO.2008.16.3758","volume":"26","author":"H Wilke","year":"2008","unstructured":"Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol. 2008;26(33):5335\u201343.","journal-title":"J Clin Oncol"},{"issue":"2","key":"964_CR40","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","volume":"3","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211\u20139.","journal-title":"JAMA Oncol"},{"issue":"9","key":"964_CR41","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00384-015-2273-z","volume":"30","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Ma J, Zhang S, Deng G, Wu X, He J, et al. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis. 2015;30(9):1173\u201383.","journal-title":"Int J Colorectal Dis"},{"issue":"10","key":"964_CR42","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065\u201375.","journal-title":"Lancet Oncol"},{"issue":"10","key":"964_CR43","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","volume":"25","author":"E Missiaglia","year":"2014","unstructured":"Missiaglia E, Jacobs B, D\u2019ario G, Di Narzo A, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995\u20132001.","journal-title":"Ann Oncol"},{"issue":"5","key":"964_CR44","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1158\/1078-0432.CCR-17-2484","volume":"24","author":"JM Loree","year":"2018","unstructured":"Loree JM, Pereira AA, Lam M, Willauer AN, Raghav K, Dasari A, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2018;24(5):1062\u201372.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"964_CR45","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1158\/1078-0432.CCR-15-0527","volume":"21","author":"FA Sinicrope","year":"2015","unstructured":"Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, et al. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (alliance). Clin Cancer Res. 2015;21(23):5294\u2013304.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"964_CR46","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard J-Y, Peeters M, Lenz H-J, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713\u201329.","journal-title":"Ann Oncol"},{"key":"964_CR47","doi-asserted-by":"crossref","unstructured":"Brule S, Jonker D, Karapetis C, O\u2019Callaghan CJ, Moore M, Wong R, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO. 17. Eur J Cancer. 2015;51(11):1405\u201314.","DOI":"10.1016\/j.ejca.2015.03.015"},{"issue":"3","key":"964_CR48","first-page":"1","volume":"34","author":"F Wang","year":"2015","unstructured":"Wang F, Bai L, Liu TS, Yu YY, He MM, Liu KY, et al. Right-and left-sided colorectal cancers respond differently to cetuximab. Cancer Commun. 2015;34(3):1\u201310.","journal-title":"Cancer Commun"},{"key":"964_CR49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87\u201398.","journal-title":"Eur J Cancer"},{"issue":"2","key":"964_CR50","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194\u2013201.","journal-title":"JAMA Oncol"},{"key":"964_CR51","doi-asserted-by":"crossref","unstructured":"Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. JNCI: J Natl Cancer Inst. 2015;107(3).","DOI":"10.1093\/jnci\/dju427"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-00964-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-023-00964-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-00964-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:36:17Z","timestamp":1715762177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-023-00964-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1007\/s12029-023-00964-x","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]},"assertion":[{"value":"12 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was submitted and approved by the Research Ethics Committee of the Hospital de C\u00e2ncer de Barretos, registered by CAAE: 72877217.8.0000.5437, opinion number: 2.224.373.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This study was performed with the agreement of institutional board review according to internal policy for protected health information, and patients\u2019 permission for data collection was obtained by them, not by informed consent according to the retrospective design of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The authors have read the STROBE Statement\u2014a checklist of items, and the manuscript was prepared and revised according to the STROBE Statement\u2014a checklist of items.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"STROBE Statement"}},{"value":"This study evaluated OS, RAS, BRAF, and MSI frequencies in mCRC patients, refractory to previous chemotherapy and finally treated with cetuximab. The OS, NRAS, and MSI frequencies were similar those found in other studies that evaluated cetuximab in poly-treated patients. BRAF and NRAS mutations and the presence of MSI were associated with lower survival rates. Only tumour laterality remained an independent prognostic factor in a multivariate analysis.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Core Tip"}}]}}